Skip to content
Medical Health Aged Care

PHAA backs ban on engineered stone products

Public Health Association of Australia 2 mins read

27 October 2023

The country’s peak body for public health welcomes the release today of a Safe Work Australia report that recommends a ban on engineered stone.

Adjunct Professor Terry Slevin, CEO, Public Health Association of Australia says that although industry has tried to argue against a ban, it is necessary because safe levels of silica in engineered stone cannot be determined.

“The move to ban this common and extremely harmful product, having a disproportionate and rapid impact on people working with the extreme levels of exposure to silica in engineered stone, is well overdue.

 

“In public health we often see push back from industry when there are proposals to regulate a product that is causing significant harm. Industries often claim that the proposal is not perfect, and argue that is a reason for inaction.

 

“In the interests of protecting industry profits, commercial entities opposing health regulation will condemn more workers who use their products to catastrophic respiratory health problems. Given what we know now, that is simply wrong.

 

“If we applied the logic of these industries, we would never have made the progress we have in reducing smoking, protecting ourselves from the sun to reduce skin cancer, or in advancing road safety.

 

“There is certainly more work to be done to reduce lung diseases, including cancer, resulting from exposure to silica.

 

“Silica exposure is a health risk for people who work in construction, mining, tunnelling, roadwork, and many other industries.

“We urge all Work Health and Safety Ministers to accept the Safe Work Australia recommendation and ban the use of engineered stone in Australia.”

 

NOTE TO EDITORS: The PHAA is also signatory to a joint statement alongside the Australian Council of Trade Unions, Australian Institute of Health & Safety, Australian Institute of Occupational Hygienists, Cancer Council, Lung Foundation, and the Australian and New Zealand Society of Occupational Medicine Inc.

 

For further information/comment:

Paris Lord (he/him), PHAA Communications & Media Manager, 0478 587 917, plord@phaa.net.au  


Contact details:

Paris Lord (he/him), PHAA Communications & Media Manager, 0478 587 917, plord@phaa.net.au  

Media

More from this category

  • Medical Health Aged Care
  • 13/09/2024
  • 12:40
Zenas BioPharma

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Zenas. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $225.0 million. Zenas’ common stock is expected to begin trading…

  • Medical Health Aged Care
  • 13/09/2024
  • 12:31
Dementia Australia

New report reinforces dementia as chronic disease of 21st century

Updates to the Dementia in Australia report, released today by the Australian Institute of Health and Welfare (AIHW), reinforce that dementia is an urgent public health issue. Dementia is the second leading cause of death in Australia, the leading cause of death of women, the second leading cause of disease burden overall, and the leading cause of burden for people aged 65 and over. Dementia Australia CEO Professor Tanya Buchanan saidthe report highlights the enormity and impact of dementia in Australia as the chronic disease of the 21st century. “Despite the growing number of Australians diagnosed with dementia – there…

  • Medical Health Aged Care, Science
  • 13/09/2024
  • 11:08
La Trobe University

Centre to play key role in global AI medical research

Artificial intelligence promises to unlock new cures for cancer and other diseases by revolutionising the speed, cost and availability of personally designed drugs and enabling these to be tested on “digital twins" before being given to patients. AI will enable broad-spectrum like chemotherapy to be replaced by these more personalised, better targeted treatments. Scientists at La Trobe University's new Australian Centre for Artificial Intelligence in Medical Innovation (ACAMI), launched today, will also apply AI techniques to mRNA therapy development to enable faster design of more precise and effective treatments. Vice-Chancellor Professor Theo Farrell said ACAMI would sit within La Trobe’s…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.